**Prices Drop for Obesity Treatments, But Access Remains Limited**
**Meta Description:** Prices for obesity medications Wegovy and Zepbound are decreasing, yet access remains a challenge for many patients due to high costs and uneven insurance coverage.
**URL Slug:** obesity-treatment-access
**Headline:** Prices for Wegovy and Zepbound Decline, Yet Access Challenges Persist
The cost of popular obesity treatments, Wegovy and Zepbound, is decreasing, but many patients still face significant barriers to accessing these medications. For those without insurance, the monthly cost remains around $500, making it unaffordable for a large number of individuals. Even insured patients encounter inconsistent coverage, raising concerns about the sustainability of these treatments. Matt Maciejewski, a professor at Duke University specializing in obesity treatment coverage, emphasizes that while the medications should be accessible, the critical issues are their pricing and affordability.
Healthcare providers are adapting their treatment strategies due to these challenges, but there is optimism that prices may continue to decline. Wegovy and Zepbound are part of a growing class of obesity medications known as GLP-1 receptor agonists, which have gained significant traction in recent years. Zepbound generated $2.3 billion in U.S. sales in the first quarter of this year, making it one of Eli Lilly’s top products. Meanwhile, Wegovy has approximately 200,000 weekly prescriptions in the U.S. and nearly $1.9 billion in first-quarter sales.
According to the benefits consultant Mercer, more companies with 500 or more employees are beginning to offer coverage for these injectable medications to their employees and their families. Novo Nordisk reports that 85% of its U.S. patients with insurance pay $25 or less per month for Wegovy. Additionally, patients with diabetes may receive coverage for GLP-1 drugs like Ozempic and Mounjaro, which are approved for treating that condition. However, most state and federally funded Medicaid programs do not cover obesity treatments, nor does Medicare, which primarily serves individuals aged 65 and older. Even when coverage is available, it often only partially covers the costs, leaving patients with substantial out-of-pocket expenses, as noted by Dr. Beverly Tchang.
While drug manufacturers provide assistance for these costs, such support can be limited. Dr. Tchang, who advises both Novo and Lilly, points out that having coverage does not equate to having access. Employers are increasingly wary of the long-term costs associated with these medications, leading some large companies to eliminate coverage altogether. Pharmacy benefit managers (PBMs) are also beginning to favor one brand over another in their negotiations with drugmakers. For instance, CVS Health’s PBM removed Zepbound from its national formulary on July 1, opting for Wegovy instead, which has forced some doctors, like Dr. Tchang, to seek alternative treatment plans for their patients.
To help prospective patients navigate insurance coverage, Dr. Courtney Younglove’s office provides a video link that guides them on checking their insurer’s website before their appointment. Unfortunately, this often results in cancellations when patients discover they lack coverage.
In summary, while the prices of Wegovy and Zepbound are falling, access to these essential obesity treatments remains a significant hurdle for many patients due to high costs and inconsistent insurance coverage.
**FAQ:**
**Q: Why are Wegovy and Zepbound important for obesity treatment?**
A: Wegovy and Zepbound are effective medications that help manage obesity, but their high costs and limited insurance coverage create access challenges for many patients.
